Skip to content

Chinese Anti-Tumor Tablets: Investigational New Drug (IND) Application Accepted

On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company’s Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of tumors. The application has been accepted by the Center for Drug Evaluation of National Medical Products Administration of China (Application Number: CXHL2401105, CXHL2401107, CXHL2401108). Malignant tumors are one of the main causes leading to human death. Although clinical treatments have been significantly improved, most tumors are still incurable. The drug resistance, tumor recurrence and metastasis still are the biggest threat to long-term survival of patients. Particularly, Malignant brain tumors and brain metastasis  not only brings direct life hazards but also has a natural barrier for drug efficacy due to the blood-brain barrier. Therefore, developing new anti-tumor drugs with good brain permeability has become a hot and… 

more »Chinese Anti-Tumor Tablets: Investigational New Drug (IND) Application Accepted

Dehydration leads to muscle cramps in IRONMAN triathletes

PULLMAN, Washington – As athletes prepare to dive into Hawaiian waters for the first leg of the IRONMAN World Championship on Oct. 26, they might want to pay a little more attention to the water in their bodies. Contrary to previous findings, a study led by Washington State University that examined three decades of IRONMAN elite competition found a link between dehydration and exercise-induced muscle cramps. The study, published in the Clinical Journal of Sport Medicine, drew on medical data from more than 10,500 triathletes and found a strong association between dehydration and participants seeking treatment for muscle cramps during competition. While many common theories suggest that electrolyte imbalances or potassium and salt levels contribute to cramps, this study found no evidence of that, aligning with other recent research. Muscle cramps are among the most common complaints in triathlons. According to a… 

more »Dehydration leads to muscle cramps in IRONMAN triathletes

Wearable cameras allow AI to detect medication errors

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence, detects potential errors in medication delivery. In a test whose results were published today, the video system recognized and identified, with high proficiency, which medications were being drawn in busy clinical settings. The AI achieved 99.6% sensitivity and 98.8% specificity at detecting vial-swap errors. The findings are reported Oct. 22 in npj Digital Medicine. The system could become a critical safeguard, especially in operating rooms, intensive-care units and emergency-medicine settings, said co-lead author Dr. Kelly Michaelsen, an assistant professor of anesthesiology and pain medicine at the University of Washington School of Medicine. “The thought of being able to help patients in real time or to prevent a medication error before it happens is very powerful,” she said. “One can hope… 

more »Wearable cameras allow AI to detect medication errors

Rapid genome analysis of a greyhound sets new standard for species conservation research

(Pugnalom.io) The progressive global loss of biodiversity makes it increasingly necessary to quickly capture and evaluate genetic information of endangered species. The Department of Human Genetics at Bioscientia Institut für Medizinische Diagnostik GmbH in Ingelheim am Rhein and the Hessian LOEWE Center for Translational Biodiversity Genomics (LOEWE-TBG) have, in a joint project, sequenced the complete genome of a… Rapid genome analysis of a greyhound sets new standard for species conservation research

Asia’s companies expect an increase in insolvencies

In Asia, concern is growing about an increase in insolvencies in the coming months. This is according to the current 2024 edition of the Atradius Payment Practices Barometer Asia. Business-to-business (B2B) trade on credit is particularly affected by this. For half of the companies surveyed by Atradius in Asia, the increasing risk of insolvency has become one of the main concerns… Asia’s companies expect an increase in insolvencies

Lilly’s Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain

Eli Lilly and Company (NYSE: LLY) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer’s disease in eligible adults in Great Britain. Eligible patients are limited to apolipoprotein E ?4 (ApoE ?4) heterozygotes or non-carriers, which is a requirement for the class of currently approved amyloid-targeting therapies in Great Britain. Donanemab is the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed. Great Britain is the third major market to approve donanemab, marketed as Kisunla. Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead to memory and thinking…

more »Lilly’s Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain

Consumer association criticizes incorrect billing of statutory health insurance services

Some patients apparently have to pay for treatments at the doctor's office that are actually covered by health insurance. This has emerged from a consumer call by the Federation of German Consumer Organisations (VZBV), which received around 300 reports between February and September and which the Funke Mediengruppe newspapers reported on. The analysis shows that some treatments are unjustifiably classified as individual health services (IGeL) […] Consumer association criticizes incorrect billing of statutory health insurance services

Cytokine Panels Informed Clinical Management in Nearly 30% of Pediatric Cases

Researchers from Children’s Hospital of Philadelphia (CHOP) demonstrated how rapid testing of cytokine levels can help distinguish different diseases with similar symptom profiles. Nearly 30% of clinicians changed how they managed disease in children after receiving cytokine level information, showing the potential for this testing to impact clinical practice. The findings were recently published in the Journal of Allergy and Clinical Immunology. During the COVID-19 pandemic, doctors began diagnosing patients with multisystem inflammatory syndrome in children (MIS-C), a condition that occurs weeks after infection and results from inflammation throughout the body. However, the initial symptoms – such as high fever and changes in blood pressure – are very similar to those of an acute, severe COVID-19 infection, so doctors needed to be able to distinguish between the two conditions, since each one requires a very different course of treatment. Distinguishing…

more »Cytokine Panels Informed Clinical Management in Nearly 30% of Pediatric Cases

Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee (IDMC) has recommended that the trials are not futile and should continue as planned. The ongoing ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, is expected to enroll approximately 1,050 adult patients with active RMS at more than… 

more »Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Mpox in Germany: Background

  • News

Mpox, formerly known as monkeypox, remains a relevant health topic in Germany. Although case numbers have significantly decreased since the 2022 outbreak, sporadic infections still occur. In 2024, 86 Mpox cases have been reported in Germany so far, 33 of them in Berlin alone[9]. On October 18, 2024, the new Mpox variant Clade Ib was detected for the first time in Germany[1][2]. This variant, which has been spreading in Africa for some time, is considered potentially more contagious and dangerous than previous variants[7]. The affected patient had been infected abroad. Despite this individual case, the Robert Koch Institute (RKI) continues to assess the risk to the general population as low[2]. An approved vaccine is available in Germany for the prevention of Mpox. The Standing Committee on Vaccination (STIKO) recommends vaccination for specific risk groups, including men who have sex with men and frequently change partners, as well as… 

more »Mpox in Germany: Background